Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma

Published:2015-04-21 Issue:7 Volume:24 Page:897-912
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Merli Michele¹,Ferrario Andrea¹,Maffioli Margherita¹,Arcaini Luca²,Passamonti Francesco¹

Affiliation:

1. 1University Hospital Ospedale di Circolo and Fondazione Macchi, Division of Hematology, Viale L. Borri 57, 21100 Varese, Italy ;

2. 2University of Pavia, Department of Molecular Medicine and Fondazione IRCCS Policlinico San Matteo, Department of Hematology-Oncology, Pavia, Italy

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2015.1038342

Reference109 articles.

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

2. The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

3. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

4. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

5. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Blessed Union of Glycobiology and Immunology: A Marriage That Worked;Medicines;2023-01-19

2. Modulating neuroinflammation through molecular, cellular and biomaterial‐based approaches to treat spinal cord injury;Bioengineering & Translational Medicine;2022-08-31

3. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials;Journal of Clinical Pharmacy and Therapeutics;2022-07-29

4. Radioimmunotherapy of Lymphomas;Nuclear Medicine Therapy;2019

5. Combination therapy with the type II anti-CD20 antibody obinutuzumab;Expert Opinion on Investigational Drugs;2017-09-06